Complement is the Central Pathogenic Driver of HSCT-Associated TMA
Complement activation—particularly through the classical and lectin pathways—is the primary mechanism driving endothelial injury in HSCT-TMA, and complement-targeted therapies represent the most effective treatment approach for this life-threatening complication 1, 2.
Pathophysiologic Role of Complement
Complement activation serves as the central pathogenic mechanism in HSCT-TMA through the following cascade:
Endothelial injury triggers complement activation: HSCT conditioning regimens, calcineurin inhibitors, GVHD, and infections cause endothelial damage that exposes damage-associated molecular patterns (DAMPs) on endothelial cell surfaces 2
Lectin pathway activation predominates: Pattern-recognition molecules (mannose-binding lectin, collectins, ficolins) bind to DAMPs, forming complexes with MASP-1, MASP-2, and MASP-3 that drive complement activation 2
Classical pathway also contributes: Prospective data demonstrate that 26 out of 85 patients (31%) show an "activated" complement profile through the classical/lectin pathway, defined by post-transplant decline of C3/C4 and CH50 activity 3
Terminal complement activation causes organ damage: C5b-9 (membrane attack complex) deposits on endothelial cells correlate directly with histological severity of organ injury 3
Clinical Impact of Complement Activation
The prospective French multicenter trial provides the strongest evidence linking complement activation to outcomes 3:
Dramatically increased mortality: Complement activation within the first weeks post-HSCT associates with 3.69-fold increased non-relapse mortality (HR: 3.69,95% CI: 1.55-8.78, p=0.003)
Poorer overall survival: 2.72-fold worse survival (HR: 2.72,95% CI: 1.37-5.39, p=0.004)
Specific complications driven by complement:
- GI GVHD: 36.8-fold increased risk (HR: 36.8,95% CI: 12.4-109.1, p<0.001)
- TMA: 8.58-fold increased risk (HR: 8.58,95% CI: 2.16-34.08, p=0.0022)
- Capillary leak syndrome: 7.36-fold increased risk (HR: 7.36,95% CI: 2.51-21.66, p=0.00028)
- Post-engraftment bacterial infections: 2.37-fold increased risk
- EBV reactivation: 3.33-fold increased risk
Complement-Coagulation Cross-Talk
MASP-2 directly activates the coagulation cascade by cleaving prothrombin to thrombin, creating a procoagulant state that drives thrombotic complications 2. This mechanistic link explains why HSCT-TMA manifests both microangiopathic hemolysis and thrombotic organ injury.
Monitoring Complement Activation
Serial measurement of complement markers identifies high-risk patients:
- C3a elevation: Peaks at 30 minutes and 24 hours peri-transplant 4
- SC5b-9 (terminal complement complex): 50% elevation from baseline indicates significant activation; one severe TMA patient showed 40-fold elevation at 1 month post-transplant 4
- C3/C4 decline with reduced CH50 activity: Defines the "activated" complement profile associated with poor outcomes 3
Therapeutic Implications
Complement-targeted therapies have transformed HSCT-TMA from a uniformly fatal condition to a treatable disease 1:
Eculizumab (C5 inhibitor): Prospective and large cohort data demonstrate meaningful improvements in survival and organ recovery 1. Even severe cases with pulmonary hypertension and right heart failure respond 5
Narsoplimab (MASP-2 inhibitor): First FDA-approved treatment for TA-TMA, showing activity even in patients previously exposed to C5 inhibition 1
Ravulizumab (long-acting C5 inhibitor): Encouraging phase 3 results 1
Critical Pitfalls
Do not wait for complete diagnostic workup: HSCT-TMA progresses rapidly; initiate complement inhibition based on clinical diagnosis while excluding ADAMTS13 deficiency and STEC-HUS 5
Absence of thrombocytopenia does not exclude TMA: 13% of patients lack significant platelet reduction, and 38% lack significant anemia or thrombocytopenia 6
Genetic variants are not required for diagnosis: Over 40-50% of cases have no identifiable mutation, yet complement activation still drives pathology 6
Earlier non-complement therapies are ineffective: Calcineurin inhibitor modification, plasma exchange, defibrotide, and rituximab showed limited and inconsistent benefit 1
Additional Pathogenic Factors
While complement is central, HIF-1α (hypoxia-inducible factor-1α) may represent an additional driver of endothelial injury in HSCT-TMA, potentially explaining why not all patients respond to terminal complement inhibitors 7. This suggests future combination strategies may be needed for refractory cases.